Citywide implementation of a rapid whole-genome sequencing program for critically ill pediatric patients

Critically ill children in neonatal and pediatric intensive care units (NICU/PICU) often suffer from rare genetic disorders that are difficult to diagnose using conventional, sequential testing. This study evaluated the feasibility, diagnostic efficacy, and clinical utility of implementing a citywide rapid whole-genome sequencing (rWGS) program, named Little Falcon, within Dubai’s public healthcare system.

Researchers established a centralized referral network across Dubai Health to provide rWGS for 100 critically ill pediatric patients. The program utilized a multidisciplinary team—including geneticists, bioinformaticians, and counselors—to ensure rapid turnaround. The study compared these results against a matched historical cohort of 100 patients who received standard-of-care genetic testing. The analysis focused on diagnostic yield, time to diagnosis, and the resulting changes in clinical management, such as targeted therapies, surgical interventions, or palliative care decisions.

The rWGS program achieved a 53% diagnostic yield, which rose to 80% among consanguineous families. The median turnaround time was 3.4 days, a dramatic improvement over the 38-day median for the historical control group. Furthermore, rWGS led to clinically meaningful management changes in 53% of patients, compared to only 18% in the control group. The study highlights that rWGS acts as a powerful diagnostic safety net, particularly in populations with high rates of recessive disorders, and can effectively guide precision medicine even in complex, multisystemic cases.

This study demonstrates that rWGS is a scalable, high-impact diagnostic tool that can be successfully integrated into a citywide healthcare system. By providing rapid, actionable insights, rWGS reduces the diagnostic odyssey for critically ill children, enables timely life-saving interventions, and offers significant long-term value by informing reproductive counseling and preventing future disease recurrence in high-risk families.